Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:57:13.137Z.
Calculation as of: 2026-10-06T19:57:13.137Z.
Quote observation: 2026-10-06T19:55:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e4c5e5530b5f4ff9b2ae64c4564a307684e7c74323ce66c5db527ab157f5d0a0
PE RATIO
N/A
Market Cap
$3.27M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IceCure Medical Ltd (ICCM) | $2.79M | N/A | N/A | N/A | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.09M | N/A | N/A | N/A | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.01M | N/A | N/A | N/A | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $2.93M | N/A | 0.90 | 0.90 | 0.90 |
| MBody AI Ltd. (MBAI)vs › | $3.21M | N/A | N/A | N/A | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.27M | N/A | N/A | N/A | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.26M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.34M | N/A | N/A | N/A | N/A |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.80M | N/A | N/A | N/A | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.69M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.24
Forward EPS (Est.)
$-5.35
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
